Shop Now Contact

Anti-Human CD11a (Efalizumab Biosimilar)

Cat # Size Price Quantity
5024011 mg$250
5024025 mg$750
50240320 mg$1800

  Bulk/Custom

Product Details

CloneEfalizumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human CD11a (Efalizumab Biosimilar)
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman CD11a
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsLFA-1
Target NameCD11a, integrin alpha L (ITGAL), Ly-15, Ly-21, LFA-1 α subunit
Antibody TypeRecombinant
Research AreasAdhesion Molecules, Autoimmunity, Inflammation, T cells, B cells, Monocytes, Macrophages, Neutrophils, Basophils, Eosinophils
See All FormatsClone Efalizumab

Background Information

Efalizumab is a humanized monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass, engineered to specifically target the α-subunit of the leukocyte function-associated antigen-1 (LFA-1) complex, known as CD11a. Structurally, Efalizumab is composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the characteristic Y-shaped antibody structure with a molecular weight of approximately 150 kilodaltons (kDa). The antibody is produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells, ensuring proper glycosylation, folding, and assembly necessary for functional stability and activity.

The variable regions of Efalizumab, containing complementarity-determining regions (CDRs), are derived from murine sequences that confer high-affinity antigen binding, while the constant regions are of human IgG1 origin. This chimeric design maintains strong epitope specificity while improving molecular compatibility with human proteins. The CDRs form the paratope that binds specifically to CD11a, the integrin α-chain component of LFA-1, which pairs with CD18 to form a β2-integrin. By occupying this binding site, Efalizumab inhibits the interaction between LFA-1 and its natural ligand, intercellular adhesion molecule-1 (ICAM-1), located on endothelial and antigen-presenting cells. This steric blockade modulates leukocyte adhesion, migration, and costimulatory signaling, thus influencing the dynamics of T-cell activation and trafficking in experimental systems examining immune synapse formation and integrin-mediated signaling.

The Fc (fragment crystallizable) region of Efalizumab provides structural stability and prolongs serum half-life through interactions with the neonatal Fc receptor (FcRn). While IgG1 antibodies can mediate effector functions, Efalizumab was not specifically optimized for antibody-dependent cytotoxicity, as its primary action relies on receptor blockade rather than immune cell recruitment. Overall, Efalizumab exemplifies rational antibody engineering, combining precise integrin targeting with a stable immunoglobulin framework to modulate adhesion-dependent immune mechanisms in biochemical and cellular research contexts.

Data Sheets

Anti-Human CD11a (Efalizumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Mouse CD11a Antibody, Clone M17/4

iF647 Anti-Mouse CD11a Antibody, Clone M17/4

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.